medRxiv preprint doi: https://doi.org/10.1101/2020.05.01.20087130; this version posted May 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

1

Dose prediction for repurposing nitazoxanide in SARS-CoV-2

2

treatment or chemoprophylaxis

3
4
5
6
7
8

Rajith KR Rajoli1, Henry Pertinez1, Usman Arshad1, Helen Box1, Lee Tatham1, Paul Curley1, Megan
Neary1, Joanne Sharp1, Neill J Liptrott1, Anthony Valentijn1, Christopher David1, Steve P Rannard2,
Ghaith Aljayyoussi3, Shaun H Pennington3, Andrew Hill1, Marta Boffito4,5, Stephen A Ward3, Saye H
Khoo1, Patrick G Bray6, Paul M. O‚ÄôNeill2, W. Dave Hong2, Giancarlo Biagini3, Andrew Owen1.

9
10
11
12
13
14
15
16
17
18

1Department

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

Author for correspondence:
Professor Andrew Owen
Department of Molecular and Clinical Pharmacology
Materials Innovation Factory
University of Liverpool
51 Oxford Street,
Liverpool L7 3NY
United Kingdom
Email - aowen@liverpool.ac.uk
Phone - +44 (0)151 795 7129
Key words: COVID-19, SARS-CoV-2, Coronavirus, Pharmacokinetics, Lung

of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, L7
3NY, UK
2Department of Chemistry, University of Liverpool, Liverpool, L69 3BX, UK
3Centre for Drugs and Diagnostics. Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool
L3 5QA, UK
4Chelsea and Westminster NHS Foundation Trust and St Stephen‚Äôs AIDS Trust 4th Floor, Chelsea and Westminster Hospital,
369 Fulham Road, London, SW10 9NH, UK
5Jefferiss Research Trust Laboratories, Department of Medicine, Imperial College, London, W2 1PG, UK
6Pat Bray Electrical, 260D Orrell Road, Orrell, Wigan, WN5 8QZ, UK

Conflicts of interest statement
AO and SPR are Directors of Tandem Nano Ltd. AO has received research funding from ViiV, Merck,
Janssen and consultancy from Gilead, ViiV and Merck not related to the current paper. PON is currently
engaged in a collaboration with Romark LLC but this interaction did not influence the prioritisation or
conclusions in the current manuscript. No other conflicts are declared by the authors.
Funding
The authors received no funding for the current work. AO acknowledges research funding from
EPSRC (EP/R024804/1; EP/S012265/1), NIH (R01AI134091; R24AI118397), European Commission
(761104) and Unitaid (project LONGEVITY). GAB acknowledges support from the Medical Research
Council (MR/S00467X/1). GA acknowledges funding from the MRC Skills Development Fellowship.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.05.01.20087130; this version posted May 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

44

Abstract

45
46

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been declared a

47

global pandemic by the World Health Organisation and urgent treatment and prevention strategies

48

are needed. Many clinical trials have been initiated with existing medications, but assessments of

49

the expected plasma and lung exposures at the selected doses have not featured in the prioritisation

50

process. Although no antiviral data is currently available for the major phenolic circulating

51

metabolite of nitazoxanide (known as tizoxanide), the parent ester drug has been shown to exhibit in

52

vitro activity against SARS-CoV-2. Nitazoxanide is an anthelmintic drug and its metabolite tizoxanide

53

has been described to have broad antiviral activity against influenza and other coronaviruses. The

54

present study used physiologically-based pharmacokinetic (PBPK) modelling to inform optimal doses

55

of nitazoxanide capable of maintaining plasma and lung tizoxanide exposures above the reported

56

nitazoxanide 90% effective concentration (EC90) against SARS-CoV-2.

57

Methods: A whole-body PBPK model was constructed for oral administration of nitazoxanide and

58

validated against available tizoxanide pharmacokinetic data for healthy individuals receiving single

59

doses between 500 mg ‚Äì 4000 mg with and without food. Additional validation against multiple-

60

dose pharmacokinetic data when given with food was conducted. The validated model was then

61

used to predict alternative doses expected to maintain tizoxanide plasma and lung concentrations

62

over the reported nitazoxanide EC90 in >90% of the simulated population. Optimal design software

63

PopDes was used to estimate an optimal sparse sampling strategy for future clinical trials.

64

Results: The PBPK model was validated with AAFE values between 1.01 ‚Äì 1.58 and a difference less

65

than 2-fold between observed and simulated values for all the reported clinical doses. The model

66

predicted optimal doses of 1200 mg QID, 1600 mg TID, 2900 mg BID in the fasted state and 700 mg

67

QID, 900 mg TID and 1400 mg BID when given with food, to provide tizoxanide plasma and lung

68

concentrations over the reported in vitro EC90 of nitazoxanide against SARS-CoV-2. For BID regimens

69

an optimal sparse sampling strategy of 0.25, 1, 3 and 12h post dose was estimated.

70

Conclusion: The PBPK model predicted that it was possible to achieve plasma and lung tizoxanide

71

concentrations, using proven safe doses of nitazoxanide, that exceed the EC90 for SARS-CoV-2. The

72

PBPK model describing tizoxanide plasma pharmacokinetics after oral administration of nitazoxanide

73

was successfully validated against clinical data. This dose prediction assumes that the tizoxanide

74

metabolite has activity against SARS-CoV-2 similar to that reported for nitazoxanide, as has been

75

reported for other viruses. The model and the reported dosing strategies provide a rational basis for

76

the design (optimising plasma and lung exposures) of future clinical trials of nitazoxanide in the

77

treatment or prevention of SARS-CoV-2 infection.

medRxiv preprint doi: https://doi.org/10.1101/2020.05.01.20087130; this version posted May 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

78

Introduction

79
80

COVID-19 is a respiratory illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-

81

CoV-2) with noticeable symptoms such as fever, dry cough, and difficulty in breathing. There are

82

currently no effective treatment or prevention options and it has become a global health problem

83

with more than 3.1 million cases and over 217,000 deaths as of 29th April 2020 [1]. Urgent strategies

84

are required to manage the pandemic and the repurposing of already approved medicines is likely to

85

bring options forward more quickly than full development of potent and specific antivirals. Antiviral

86

drugs may have application prior to or during early infection, but may be secondary to

87

immunological interventions in later stages of severe disease [2].

88
89

Although new chemical entities (NCEs) are likely to have high potency and specificity for SARS-CoV-2,

90

full development is time consuming, costly and attrition in drug development is high [3, 4]. Drug

91

repurposing, where existing or investigational drugs could be used outside the scope of their original

92

indication may present a rapid alternative to new drug development. Several examples of successful

93

repurposing exist, including the use of the anti-angiogenic drug thalidomide for cancer and the use

94

of mifepristone for Cushing‚Äôs disease after initially being approved for termination of early

95

pregnancy [5, 6].

96
97

SARS-CoV-2 targets the angiotensin-converting enzyme 2 (ACE2) receptors that are present in high

98

density on the outer surface of lung cells. Lungs are the primary site of SARS-CoV-2 replication and

99

infection is usually initiated in the upper respiratory tract [7]. Symptoms that result in neurological,

100

renal and hepatic dysfunction are also emerging due to the expression of ACE2 receptors in these

101

organs [8-11]. Therefore, therapeutic concentrations of antiviral drugs are likely to be needed in the

102

upper airways for treatment and prevention of infection, but sufficient concentrations are also likely

103

to be required systemically for therapy to target the virus in other organs and tissues.

104
105

The scale at which antiviral activity of existing medicines are being studied for potential repurposing

106

against SARS-CoV-2 is unprecedented [12]. The authors recently reported a holistic analysis which

107

benchmarked reported in vitro activity of tested drugs against previously published pharmacokinetic

108

exposures achievable with their licenced doses [13]. Importantly, this analysis demonstrated that the

109

majority of drugs that have been studied for anti-SARS-CoV-2 activity are unlikely to achieve the

110

necessary concentrations in the plasma after administration of their approved doses. While this

111

analysis is highly influenced by the drugs selected for analysis to date and highly sensitive to the

medRxiv preprint doi: https://doi.org/10.1101/2020.05.01.20087130; this version posted May 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

112

accuracy of the reported antiviral activity data, a number of candidate agents were identified with

113

plasma exposures above the reported EC50/EC90 against SARS-CoV-2.

114
115

One such drug, nitazoxanide, is a thiazolide antiparasitic medicine used for the treatment of

116

cryptosporidiosis and giardiasis that cause diarrhoea [14, 15], and also has reported activity against

117

anaerobic bacteria, protozoa and other viruses [16]. Importantly, rapid deacetylation of nitazoxanide

118

in blood means that the major systemic species of the drug in vivo is tizoxanide, which has not yet

119

been studied for anti-SARS-CoV-2 activity. Notwithstanding, tizoxanide has been shown to exhibit

120

similar in vitro inhibitory activity to nitazoxanide for rotaviruses [17], hepatitis B and C viruses [18,

121

19], other coronaviruses, noroviruses [20] and influenza viruses [21, 22]. As another respiratory

122

virus, previous work on influenza may be useful to gain insight into the expected impact of

123

nitazoxanide for SARS-CoV-2. Accordingly, the drug has been shown to selectively block the

124

maturation of the influenza hemagglutinin glycoprotein at the post-translational stage [22, 23] and a

125

previous phase 2b/3 trial demonstrated a reduction in symptoms and viral shedding at a dose of 600

126

mg BID compared to placebo in patients with uncomplicated influenza [24]. Other potential benefits

127

of nitazoxanide in COVID-19 may derive from its impact upon the innate immune response that

128

potentiates the production of type 1 interferons [25, 26] and bronchodilation of the airways through

129

inhibition of TMEM16A ion channels [27]. A clinical trial (NCT04341493) started on April 6th 2020 and

130

aims to evaluate the activity of 500 mg BID nitazoxanide alone or in combination with the 4-

131

aminoquinoline hydroxychloroquine against SARS-CoV-2 [28]. However, there are currently no data

132

within the public domain to support this dose selection for COVID-19. Nitazoxanide is relatively safe

133

in humans and studies showed tolerability of single oral doses up to 4 g with minimal

134

gastrointestinal side effects. Plasma concentrations of tizoxanide have demonstrated dose

135

proportionality, but administration in the fed state increases the plasma exposure [29]. Thus, the

136

drug is recommended for administration with food.

137
138

Physiologically-based pharmacokinetic (PBPK) modelling is a computational tool that integrates

139

human physiology and drug disposition kinetics using mathematical equations to inform the

140

pharmacokinetic exposure using in vitro and drug physicochemical data [30]. The aim of this study

141

was to validate a PBPK model for tizoxanide following administration of nitazoxanide. Once validated

142

this model was first used to assess the plasma and lung exposures estimated to be achieved during a

143

previous trial for uncomplicated influenza. Next, different nitazoxanide doses and schedules were

144

simulated to identify those expected to provide tizoxanide plasma and lung trough concentrations

145

(Ctrough) above the reported nitazoxanide SARS-CoV-2 EC90 in the majority (>90%) of patients.

medRxiv preprint doi: https://doi.org/10.1101/2020.05.01.20087130; this version posted May 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

146

Methods

147
148

A whole-body PBPK model consisting of compartments to represent select organs and tissues was

149

developed. Nitazoxanide physiochemical and drug-specific parameters used in the PBPK model were

150

obtained from literature sources as outlined in Table 1. The PBPK model was assumed to be blood-

151

flow limited, with instant and uniform distribution in each tissue or organ and no reabsorption from

152

the large intestine. Since the data is computer generated, no ethics approval was required for this

153

study.

154
155

Table 1 Nitazoxanide input parameters for the PBPK model
Parameter

Nitazoxanide

Tizoxanide

307.282 [15]

265.25 [31]

>99% [15]

>99% [32]

Log P

1.63 [15]

3.2 [31]

pKa (acidic)

8.3 [15]

6.7 [33]

R

0.55

0.55

Number of hydrogen bond donors

1 [15]

2 [31]

Polar surface area

114.11 [15]

136 [31]

Apparent permeability (cm/s)

1.11e-4 [34]

-

Apparent clearance (L/h)

-

19.34 ¬± 4.97 [35]

Volume of distribution (L)

-

38.68 ¬± 14.02 [35]

Half-life (h)

-

1.38 ¬± 0.29 [35]

Molecular weight
*

Protein binding

156

R ‚Äì blood to plasma ratio was predicted from Paix√£o et al. [36], ‚Äì not available, apparent permeability was

157

assessed in HT29-19A cells and this value was considered the same in caco-2 cells for tizoxanide, *protein

158

binding was considered as 99% for the PBPK model

159
160

Model development

161

One hundred virtual healthy adults (50% women, aged 20-60 years between 40-120 kg) were

162

simulated. Patient demographics such as weight, BMI and height were obtained from CDC charts

163

[37]. Organ weight/volumes and blood flow rates in humans were obtained from published

164

literature sources [38, 39]. Transit from the stomach and small intestine was divided into seven

165

compartments to capture effective absorption kinetics as previously described [40]. Tissue to plasma

166

partition ratio of drug and drug disposition across various tissues and organs were described using

167

published mathematical equations [41-43]. Effective permeability (Peff) in humans was scaled from

168

apparent permeability (Papp) in HT29-19A cells (due to lack of available data, it was assumed the

medRxiv preprint doi: https://doi.org/10.1101/2020.05.01.20087130; this version posted May 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

169

same in Caco-2 cells) using the following equations to compute the rate of absorption (Ka in h-1) from

170

the small intestine.

171
172

log10 ùëÉùëíùëìùëì = 0.6836 √ó log10 ùëÉùëéùëùùëù ‚àí 0.5579

[44]

173
174

ùêæùëé =

2√óùëÉùëíùëìùëì √ó60√ó60
ùëü

[45]

175
176

Model validation

177

The PBPK model was validated against available clinical data in healthy individuals in the fed and

178

fasted state for various single oral doses of nitazoxanide ranging from 500 mg to 4000 mg [29, 46],

179

and for multiple dosing at 500 mg and 1000 mg BID with food. Nitazoxanide absorption was

180

considered using the available apparent permeability data (shown in table 1) and tizoxanide was

181

assumed to form as soon as the drug reached systemic circulation as metabolic studies have shown

182

it takes just six minutes for complete conversion into the active circulating metabolite, with no trace

183

of nitazoxanide detected in plasma [47]. Therefore, tizoxanide parameters were used to define drug

184

disposition. The model was assumed to be validated if: 1) the absolute average fold error (AAFE)

185

between the observed and the simulated plasma concentrations - time curve of tizoxanide was less

186

than two; and 2) the simulated pharmacokinetic parameters - maximum concentration (Cmax), area

187

under the plasma concentration-time curve (AUC) and Ctrough (trough concentration at the end of the

188

dosing interval) were less than two-fold from the mean observed values.

189
190

Model simulations

191

The pharmacokinetics following administration of 600 mg BID as reported in a previous phase 2b/3

192

clinical trial of nitazoxanide in uncomplicated influenza [24] were first simulated and plotted relative

193

to the average of previously reported influenza EC90s [48, 49] for strains(as shown in supplementary

194

table 1) included in the previous trials. This was done to assess the exposure relative to in vitro

195

activity for an indication where clinical benefit was already demonstrated.

196
197

For potential SARS-CoV-2 applications, several oral dosing regimens were simulated for BID, TID or

198

QID administration in the fasted state. Antiviral activity data from Wang et al. [50] were digitised

199

using Web Plot Digitiser¬Æ software and used to calculate a nitazoxanide EC90 for SARS-CoV-2 of 4.64

200

¬µM (1.43 mg/L). Optimal doses were identified such that the concentration at 12 hours post-first

201

dose (C12) for BID, 8 hours post-first dose (C8) for TID, or 6 hours post-first dose (C6) for QID

202

administration were over the recalculated EC90 for nitazoxanide. Plasma and lung tizoxanide

medRxiv preprint doi: https://doi.org/10.1101/2020.05.01.20087130; this version posted May 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

203

exposures at these doses and schedules are reported in addition to plasma-time curves. The doses

204

were optimised using tizoxanide parameters and pharmacokinetics, however, the doses were

205

reported for nitazoxanide.

206
207

Optimal pharmacokinetic sampling

208

Clinical trials should incorporate PK sampling to confirm tizoxanide plasma exposures, and further

209

validate the predictions from the PBPK model. Optimal sparse pharmacokinetic timepoint selection

210

(assuming 4 blood samples per patient, and 40 patients in the study) were made on the basis of the

211

prior fed PK data of Stockis et al. [29, 46]. Tizoxanide plasma PK data in fed patients from Stockis et

212

al. was fitted with an empirical one compartment disposition model, with first-order absorption and

213

absorption transit compartment, and the parameters from this fitting were used (with nominal %CV

214

interindividual variability in the PK parameters of 30%) in the optimal design software PopDes

215

(University of Manchester Version 4.0) to generate the suggested optimal sampling timepoints [51,

216

52].

217

medRxiv preprint doi: https://doi.org/10.1101/2020.05.01.20087130; this version posted May 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

218

Results

219

Model validation

220

The PBPK model validation against various fasted oral doses is shown in supplementary Figure 1 and

221

the validation against single and multiple doses in the fed state is shown in supplementary Figure 2.

222

The corresponding pharmacokinetic parameters (AUC, Cmax and Ctrough) are presented in Table 2a and

223

2b. The AAFE values for the validated doses ranged between 1.01 ‚Äì 1.55 for fasted state and

224

between 1.1 ‚Äì 1.58 for fed state indicating a close match between observed and simulated data. The

225

ratio between the simulated and the observed pharmacokinetic parameters ‚Äì AUC, Cmax and Ctrough

226

was between 0.81 ‚Äì 1.54 (Table 2a) for fasted state and between 0.67 ‚Äì 2.15 for fed state. The PBPK

227

model simulated tizoxanide plasma concentrations were within acceptable ranges and therefore the

228

PBPK model was assumed to be validated.

229

Model simulations

230

Figure 1a and 1b show the simulated plasma and lung exposures relative to the average influenza

231

EC90 after administration of 600 mg BID dose of nitazoxanide with food as reported in the previous

232

phase 2b/3 trial in uncomplicated influenza [24]. These simulations indicate that all patients were

233

predicted to have plasma and lung tizoxanide Ctrough (C12) concentrations below the average EC90 (8.4

234

mg/L, supplementary table 1) [49], but that 71% and 14% were predicted to have plasma and lung

235

Cmax concentrations respectively above the average EC90 for influenza, respectively.

236
237

Figure 2a and 2b shows the prediction of trough concentrations in plasma and lung for the different

238

simulated doses and schedules in healthy individuals for fasted and fed states, respectively. Doses

239

and schedules estimated to provide plasma Ctrough concentrations over 1.43 mg/L for at least 50% of

240

the simulated population were identified. However, lower doses in each schedule (i.e. 800 mg QID,

241

1300 mg TID and 1800 mg BID in fasted state and 500 mg QID, 700 mg TID, 1100 mg BID in fed state)

242

were predicted to result in >40% of the simulated population having lung Ctrough below the SARS-CoV-

243

2 EC90. Optimal doses for SARS-CoV-2 in the fasted state were predicted to be 1200 mg QID, 1600 mg

244

TID, 2900 mg BID and in the fed state were 700 mg QID, 900 mg TID and 1400 mg BID. Figure 3

245

shows the plasma and lung concentrations for the optimal doses and schedules in fed state and

246

supplementary figure 3 shows the plasma concentration ‚Äì time profile of optimal doses in fasted

247

state. Tizoxanide concentrations in lung and plasma were predicted to reach steady state in <48

248

hours, both in the fasted and fed state.

medRxiv preprint doi: https://doi.org/10.1101/2020.05.01.20087130; this version posted May 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

249

250
251

Figure 1 Stimulated plasma (a) and lung (b) concentration for nitazoxanide 600 mg BID for 5 days

252

with food relative to the average reported tizoxanide EC90 value for influenza strains (supplementary

253

table 1) similar to those in a previous phase IIb/III trial in uncomplicated influenza [24].

254

255

Table 2a Tizoxanide validation against observed data for various single oral doses in the fasted state

Dose (mg)
500 [46]

Pharmacokinetic parameter
*AUC
0-12 h
*C
max

(¬µg/ml)

‚Ä†C
trough

1000 [29]

(¬µg/ml)

^AUC
0-24 h
^C
max

(¬µg/ml)

^AUC
0-24 h
^C
max

(¬µg.h/ml)

(¬µg/ml)

^‚Ä†C
trough

4000 [29]

(¬µg/ml)

^AUC
0-24 h
^C
max

(¬µg.h/ml)

(¬µg/ml)

^‚Ä†C
trough

3000 [29]

(¬µg.h/ml)

(¬µg/ml)

‚Ä†C
trough

2000 [29]

(¬µg/ml)

^AUC
0-24 h
^C
max

(¬µg.h/ml)

(¬µg.h/ml)

(¬µg/ml)

^‚Ä†C
trough

(¬µg/ml)

Observed

Simulated

Simulated/observed

27.02 ¬± 6.24

24.32 ¬± 5.07

0.90

6.80 ¬± 1.32

6.47 ¬± 1.17

0.95

0.106

0.119 ¬± 0.185

1.12

50.6 (29.0 ‚Äì 88.4)

48.9 (34.3 ‚Äì 63.4)

0.93

12.3 (8.21 ‚Äì 18.3)

12.9 (10.2 ‚Äì 12.9)

1.05

0.23

0.21 (0.09 ‚Äì 0.53)

0.93

59.2 (36.5 ‚Äì 95.9)

68.5 (48.9 ‚Äì 84.1)

1.12

9.08 (7.07 ‚Äì 11.7)

9.45 (7.18 ‚Äì 11.7)

1.04

1.49

1.33 (0.45 ‚Äì 2.21)

0.89

52.9 (34.6 ‚Äì 81.0)

42. 6 (31.7 ‚Äì 53.6)

0.81

7.39 (6.07 ‚Äì 8.98)

7.51 (5.68 ‚Äì 9.33)

1.02

0.6

0.93 (0.79 ‚Äì 1.06)

1.54

88.5 (53.5 ‚Äì 146)

76.9 (60.1 ‚Äì 93.8)

0.87

10.5 (8.16 ‚Äì 13.5)

9.58 (7.34 ‚Äì 11.8)

0.91

2.48

2.44 (2.19 ‚Äì 2.67)

0.98

256

*

Cmax and AUC0-12h are represented as arithmetic mean ¬± SD, ^Cmax and AUC0-24h are represented as geometric mean (mean ‚Äì SD, mean + SD), ‚Ä†Ctrough is C12 and

257

has been digitised from the pharmacokinetic curve as the geometric mean is not available, arithmetic mean is shown for observed and arithmetic mean

258

(mean - SD, mean + SD) are shown for simulated data, ^Cmax, AUC0-24h and ^Ctrough were normalised to a 1000 mg dose.

259

Table 2b Tizoxanide validation against observed data for various single and multiple oral doses when given with food.

Dose (mg)
500 (single) [53]

Pharmacokinetic parameter
*AUC
0-last

(¬µg.h/ml)

Cmax (¬µg/ml)
‚Ä†C
trough

(¬µg/ml)

500 BID

*AUC
0-12 h

(multiple) [53]

Cmax (¬µg/ml)
‚Ä†C
trough

(¬µg.h/ml)

(¬µg/ml)

1000 (single)

*AUC
0-last

[53]

Cmax (¬µg/ml)
‚Ä†C
trough

(¬µg.h/ml)

(¬µg/ml)

1000 BID

*AUC
0-12 h

(multiple) [53]

Cmax (¬µg/ml)
‚Ä†C
trough

(¬µg.h/ml)

(¬µg/ml)

2000 (single)

^AUC
0-24 h

[29]

^C
max

(¬µg.h/ml)

(¬µg/ml)

^‚Ä†C
trough

(¬µg/ml)

3000 (single)

^AUC
0-24 h

[29]

^C
max

(¬µg.h/ml)

(¬µg/ml)

^‚Ä†C
trough

(¬µg/ml)

Observed

Simulated

Simulated/observed

41.8 (36.1 ‚Äì 48.4)

33.2 (23.1 - 43.2)

0.79

10.4 (8.65 ‚Äì 12.6)

8.08 (6.17 - 9.98)

0.78

0.178

0.28 (0 - 0.5)

1.56

48.7 (36.0 ‚Äì 65.9)

32.8 (19.5 - 46.1)

0.67

9.05 (7.13 ‚Äì 11.5)

7.66 (5.89 - 9.44)

0.85

0.310

0.35 (0 - 0.89)

1.11

85.9 (68.8 ‚Äì 107)

91.3 (69 - 113.5)

1.06

14.4 (10.8 ‚Äì 19.2)

17.8 (14.3 - 21.3)

1.23

0.786

1.43 (0.2 - 2.22)

1.82

144 (105 ‚Äì 198)

90.9 (69 - 112.8)

0.63

24.2 (20.3 ‚Äì 28.7)

18.2 (14.4 - 21.9)

0.75

1.68

1.38 (0.33 - 2.07)

0.82

110 (88.0 ‚Äì 139)

109 (74.8 - 142)

0.99

15.8 (13.0 ‚Äì 19.2)

14.3 (11.2 - 17.4)

0.91

1.52

3.27 (1.73 - 4.46)

2.15

95.3 (60.0 ‚Äì 152)

90 (60.9 - 119)

0.94

10.0 (7.40 ‚Äì 13.5)

10.4 (8.09 - 12.7)

1.04

2.35

2.64 (1.44 - 3.56)

1.12

4000 (single)

^AUC
0-24 h

[29]

^C
max

(¬µg.h/ml)

(¬µg/ml)

^‚Ä†C
trough

(¬µg/ml)

192 (99.5 ‚Äì 370)

161 (125 - 196)

0.84

17.5 (11.5 ‚Äì 26.5)

14.2 (11.2 - 17.2)

0.81

6.55

6.52 (5.04 - 7.84)

0.99

260

Cmax and AUC are represented as geometric mean (mean ‚Äì SD, mean + SD) and ^Cmax and AUC0-24h were normalised to a 1000 mg dose, ^Cmax and AUC0-24h

261

were normalised to a 1000 mg dose, *AUC is represented as AUC0-‚àû after the first dose for single and AUC0-12 on day 7, ‚Ä†Ctrough is C12 has been digitised from

262

the pharmacokinetic curve as the geometric mean is not available, arithmetic mean is shown for observed and arithmetic mean (mean - SD, mean + SD) are

263

shown for simulated data.

264
265

Figure 2a Predicted tizoxanide Ctrough (BID ‚Äì 12 h, TID ‚Äì 8 h, QID ‚Äì 6 h) for various dosing regimens of nitazoxanide in fasted state at the end of the first dose.

266

Data is presented as mean and error bars represent standard deviation. The percentages adjacent to the bar chart indicate the percentage of simulated

267

population over EC90 of nitazoxanide for SARS-CoV-2.

268
269

Figure 2b Predicted tizoxanide Ctrough (BID ‚Äì 12 h, TID ‚Äì 8 h, QID ‚Äì 6 h) for various dosing regimens of nitazoxanide in fed state at the end of the first dose.

270

Data is presented as mean and error bars represent standard deviation. The percentages adjacent to the bar chart indicate the percentage of simulated

271

population over EC90 of nitazoxanide for SARS-CoV-2.

medRxiv preprint doi: https://doi.org/10.1101/2020.05.01.20087130; this version posted May 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

272

A)

273
274

275
276

B)

medRxiv preprint doi: https://doi.org/10.1101/2020.05.01.20087130; this version posted May 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

C)

277
278

Figure 3 Predicted plasma and lung concentrations for optimal doses during the fed state at different

279

regimens reaching steady state ‚Äì A) 1400 mg BID, B) 900 mg TID and C) 700 mg QID. TIZ ‚Äì tizoxanide,

280

SD ‚Äì standard deviation, solid red line indicates clinical Cmax of 1 g single dose at fed state [29], solid

281

green line represents clinical Cmax of 500 mg single dose [53] at fed state and the dotted red line

282

represents the EC90 of nitazoxanide for SARS-CoV-2 [50].

283
284

Optimal sparse sampling design

285

Results from PopDes optimal design procedure indicate pharmacokinetic sampling timepoints at

286

0.25, 1, 3 and 12h post dose for BID regimens, and 0.25, 1, 2 and 8h post dose for TID regimens.

medRxiv preprint doi: https://doi.org/10.1101/2020.05.01.20087130; this version posted May 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

287

Discussion

288

Treatment of SARS-CoV-2 has become a major global healthcare challenge with no well-defined

289

therapeutic agents to either treat or prevent the spread of the infection. Short-term treatment

290

options are urgently required but many ongoing trials are not based upon a rational selection of

291

candidates in the context of safe achievable drug exposures. In the absence of a vaccine, there is

292

also an urgent need for chemo preventative strategies to protect those at high risk such as

293

healthcare staff, key workers and household contacts who are more vulnerable to infection.

294

Nitazoxanide has emerged as a potential candidate for repurposing for COVID-19. The PBPK model

295

presented herein was validated with an acceptable variation in AAFE and simulated/observed ratio

296

(close to 1), which provides confidence in the presented predictions. The present study aimed to

297

define the optimal doses and schedules for maintaining tizoxanide plasma and lung concentrations

298

above the reported nitazoxanide EC90 for the duration of the dosing interval.

299
300

Nitazoxanide was assessed in a double-blind, randomised, placebo-controlled, phase 2b/3 trial

301

(NCT01227421) of uncomplicated influenza in 74 primary care clinics in the USA between 27 Dec

302

2010 and 30 April 2011 [54]. The median duration of symptoms for patients receiving placebo was

303

117 h compared with 96 h in patients receiving 600 mg BID nitazoxanide with food. Importantly,

304

virus titre in nasopharyngeal swabs in 39 patients receiving nitazoxanide 600 mg BID were also lower

305

than in 41 patients receiving placebo. The average of reported tizoxanide EC90s for influenza A and B

306

[55] was calculated to be 8.4 mg/L, which is higher than the one reported EC90 for nitazoxanide

307

against SARS-CoV-2 [50]. The PBPK model was used to simulate plasma and lung exposures after

308

administration of 600 mg BID for 5 days, and while only plasma Cmax exceeded the average influenza

309

EC90 in the majority of patients, the Ctrough values did not. The modelling data suggest that the

310

moderate effects of nitazoxanide seen in influenza could be a function of under dosing. Taken

311

collectively, these data are encouraging for the application of nitazoxanide in COVID-19, assuming

312

that tizoxanide displays anti-SARS-CoV-2 activity comparable to that reported for nitazoxanide.

313

Moreover, these simulations indicate that higher doses may be optimal for maximal suppression of

314

pulmonary viruses.

315
316

In some cases, food intake may be difficult in patients with COVID-19 so drugs that can be given

317

without regard for food may be preferred. However, the presented predictions indicate that optimal

318

plasma and lung exposures would require 1200 mg QID, 1600 mg TID or 2900 mg BID in the fasted

319

state. Conversely, the PBPK models predict that doses of 700 mg QID, 900 mg TID or 1400 mg BID

320

with food provide tizoxanide concentrations in plasma and lung above the EC90 value for

medRxiv preprint doi: https://doi.org/10.1101/2020.05.01.20087130; this version posted May 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

321

nitazoxanide for the entire dosing interval in at least 90% of the simulated population. Single doses

322

up to 4000 mg have been administered to humans previously [29] but the drug is usually

323

administered at 500 mg BID.. The PBPK model simulations indicate a high BID dose of 1400 mg (fed)

324

and caution may be needed for gastrointestinal intolerance at this dose. The simulations indicate

325

that lower TID and QID dosing regimens may also warrant investigation, and 900 mg TID as well as

326

700 mg QID (both with food) regimen are also predicted to provide optimal exposures for efficacy.

327

Importantly, the overall daily dose was estimated to be comparable between the different optimal

328

schedules and it is unclear whether splitting the dose will provide gastrointestinal benefits. For

329

prevention application where individuals will need to adhere to regimens for longer durations,

330

minimising the frequency of dosing is likely to provide adherence benefits. However, for short term

331

application in therapy, more frequent dosing may be more acceptable to minimise gastrointestinal

332

intolerance.

333
334

Nitazoxanide mechanism of action for SARS-CoV-2 is currently unknown. However, for influenza it

335

has been reported to involve interference with N-glycosylation of hemagglutinin [22, 55, 56]. Since

336

the SARS-CoV-2 spike protein is also heavily glycosylated [57] with similar cellular targets in the

337

upper respiratory tract, a similar mechanism of action may be expected [7, 58]. An ongoing trial in

338

Mexico, is being conducted with 500 mg BID nitazoxanide with food [28] but these doses may not be

339

completely optimal for virus suppression across the entire dosing interval.

340
341

This analysis provides a rational dose optimisation for nitazoxanide for treatment and prevention of

342

COVID-19. However, there are some important limitations that must be considered. PBPK models

343

can be useful in dose prediction but the quality of predictions is only as good as the quality of the

344

available data on which they are based. Furthermore, the mechanism of action for nitazoxanide for

345

other viruses has also been postulated to involve an indirect mechanism through amplification of the

346

host innate immune response [59], and this would not have been captured in the in vitro antiviral

347

activity that informed the target concentrations for this dose prediction. The simulated population

348

used in this modelling consisted of healthy individuals up to 60 years old, but many patients

349

requiring therapy may be older and have underlying comorbidities. To best knowledge, the impact of

350

renal and hepatic impairment on pharmacokinetics of this drug have not been assessed and may

351

impact the pharmacokinetics. Although the current PBPK model is validated against various single

352

doses in the fasted state and few multiple doses when given with food, the model may predict with

353

less accuracy for multiple doses due to the unavailability of clinical data for multiple dosing over

354

1000 mg. The presented models were validated using BID doses only, and confidence in the

medRxiv preprint doi: https://doi.org/10.1101/2020.05.01.20087130; this version posted May 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

355

predictions for TID and QID doses may be lower. The clinical studies used for model validation were

356

performed in a limited number of patients [29] and thus may underrepresent real inter-subject

357

variability. Also, the disposition parameters (apparent clearance and rate of absorption) obtained for

358

the PBPK model were from a fasted study of 500 mg BID, and the parameters were adjusted to

359

validate the tizoxanide model in the fed state, which may limit confidence in the model at higher

360

doses. Only one manuscript has described the in vitro activity of nitazoxanide against SARS-CoV-2

361

[50] and no data are available for tizoxanide. Reported in vitro data may vary across laboratories and

362

due to this the predicted optimal doses may change. However, the reported comparable activity of

363

nitazoxanide and tizoxanide against a variety of other viruses (including other coronaviruses) does

364

strengthen the rational for investigating this drug for COVID-19 [17-19, 21, 22]. Finally, none of the

365

reported EC90 values for influenza or SARS-CoV-2 were protein binding-adjusted [50] and tizoxanide

366

is known to be highly protein bound (>99%) in plasma [32]. Therefore, while the protein binding was

367

used to estimate drug penetration into the lung, data were not available to correct the in vitro

368

activity.

369
370

In summary, the developed PBPK model of nitazoxanide was successfully validated against clinical

371

data and based on currently available data, optimal doses for COVID-19 were estimated to be 700

372

mg QID, 900 mg TID or 1400 mg BID with food. Should nitazoxanide be progressed into clinical

373

evaluation for treatment and prevention of COVID-19, it will be important to further evaluate the

374

pharmacokinetics in these population groups. In treatment trials particularly, intensive

375

pharmacokinetic sampling may be challenging. Therefore, an optimal sparse sampling strategy for

376

BID, TID and QID dosing is also presented.

377

medRxiv preprint doi: https://doi.org/10.1101/2020.05.01.20087130; this version posted May 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

378

References

379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428

1.
2.

3.
4.
5.
6.
7.
8.

9.
10.
11.

12.
13.

14.

15.
16.

17.

18.
19.
20.

21.

Johns Hopkins University of Medicine. Coronavirus Resource Center. 2020 [cited 2020
17/04/2020]; Available from: https://coronavirus.jhu.edu/map.html.
Zhang, W., et al., The use of anti-inflammatory drugs in the treatment of people with severe
coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China.
Clinical immunology (Orlando, Fla.), 2020. 214: p. 108393-108393.
Gns, H.S., et al., An update on Drug Repurposing: Re-written saga of the drug‚Äôs fate.
Biomedicine & Pharmacotherapy, 2019. 110: p. 700-716.
Charlton, R.L., et al., Repurposing as a strategy for the discovery of new anti-leishmanials:
the-state-of-the-art. Parasitology, 2018. 145(2): p. 219-236.
Telleria, C.M., Drug Repurposing for Cancer Therapy. Journal of cancer science & therapy,
2012. 4(7): p. ix-xi.
Senanayake, S.L., Drug repurposing strategies for COVID-19. Future Drug Discovery, 2020.
2(2): p. null.
Shereen, M.A., et al., COVID-19 infection: Origin, transmission, and characteristics of human
coronaviruses. Journal of Advanced Research, 2020. 24: p. 91-98.
Adhikari, S.P., et al., Epidemiology, causes, clinical manifestation and diagnosis, prevention
and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping
review. Infectious Diseases of Poverty, 2020. 9(1): p. 29.
Zhu, N., et al., A Novel Coronavirus from Patients with Pneumonia in China, 2019. New
England Journal of Medicine, 2020. 382(8): p. 727-733.
Xu, H., et al., High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral
mucosa. International Journal of Oral Science, 2020. 12(1): p. 8.
Toljan, K., Letter to the Editor Regarding the Viewpoint ‚ÄúEvidence of the COVID-19 Virus
Targeting the CNS: Tissue Distribution, Host‚ÄìVirus Interaction, and Proposed Neurotropic
Mechanism‚Äù. ACS Chemical Neuroscience, 2020. 11(8): p. 1192-1194.
Sanders, J.M., et al., Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A
Review. JAMA, 2020.
Arshad, U., et al., Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities
based on ability to achieve adequate target site concentrations derived from their
established human pharmacokinetics. medRxiv, 2020: p. 2020.04.16.20068379.
Wilson, C.M., 296 - Antiparasitic Agents, in Principles and Practice of Pediatric Infectious
Diseases (Fourth Edition), S.S. Long, Editor. 2012, Content Repository Only!: London. p. 15181545.e3.
DrugBank. Nitazoxanide. 2020 [cited 2020 17/04/2020]; Available from:
https://www.drugbank.ca/drugs/DB00507.
Keiser, J. and J. Utzinger, Chapter 8 - The Drugs We Have and the Drugs We Need Against
Major Helminth Infections, in Advances in Parasitology, X.-N. Zhou, et al., Editors. 2010,
Academic Press. p. 197-230.
Rossignol, J.F. and Y.M. El-Gohary, Nitazoxanide in the treatment of viral gastroenteritis: a
randomized double-blind placebo-controlled clinical trial. Alimentary Pharmacology &
Therapeutics, 2006. 24(10): p. 1423-1430.
Korba, B.E., et al., Potential for Hepatitis C Virus Resistance to Nitazoxanide or Tizoxanide.
Antimicrobial Agents and Chemotherapy, 2008. 52(11): p. 4069-4071.
Korba, B.E., et al., Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of
hepatitis B virus and hepatitis C virus replication. Antiviral Research, 2008. 77(1): p. 56-63.
Dang, W., et al., Nitazoxanide Inhibits Human Norovirus Replication and Synergizes with
Ribavirin by Activation of Cellular Antiviral Response. Antimicrobial Agents and
Chemotherapy, 2018. 62(11): p. e00707-18.
Koszalka, P., D. Tilmanis, and A.C. Hurt, Influenza antivirals currently in late-phase clinical
trial. Influenza and other respiratory viruses, 2017. 11(3): p. 240-246.

medRxiv preprint doi: https://doi.org/10.1101/2020.05.01.20087130; this version posted May 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477

22.
23.

24.

25.
26.
27.

28.
29.

30.

31.
32.
33.

34.

35.

36.
37.

38.
39.

40.
41.

Rossignol, J.-F., Nitazoxanide: A first-in-class broad-spectrum antiviral agent. Antiviral
Research, 2014. 110: p. 94-103.
Pizzorno, A., et al., Drug Repurposing Approaches for the Treatment of Influenza Viral
Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy. Frontiers in Immunology,
2019. 10(531).
Haffizulla, J., et al., Effect of nitazoxanide in adults and adolescents with acute
uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial.
Lancet Infect Dis, 2014. 14(7): p. 609-18.
Rossignol, J.F., Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res,
2014. 110: p. 94-103.
Clerici, M., et al., The anti-infective Nitazoxanide shows strong immumodulating effects
(155.21). 2011. 186(1 Supplement): p. 155.21-155.21.
Miner, K., et al., Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are
Potent TMEM16A Antagonists That Fully Bronchodilate Airways. Frontiers in pharmacology,
2019. 10: p. 51-51.
ClinicalTrials.gov. Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19. 2020
[cited 2020 17/04/2020]; Available from: https://clinicaltrials.gov/ct2/show/NCT04341493.
Stockis, A., et al., Nitazoxanide pharmacokinetics and tolerability in man using single
ascending oral doses. International Journal of Clinical Pharmacology and Therapeutics, 2002.
40(5): p. 213-220.
Yao, X., et al., In Vitro Antiviral Activity and Projection of Optimized Dosing Design of
Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2). Clinical Infectious Diseases, 2020.
Pubchem. Tizoxanide. 2020 [cited 2020 24/04/2020]; Available from:
https://pubchem.ncbi.nlm.nih.gov/compound/Tizoxanide.
Drugs.com. Nitazoxanide. 2020 [cited 2020 18/04/2020]; Available from:
https://www.drugs.com/ppa/nitazoxanide.html.
Shalan, S., J.J. Nasr, and F. Belal, Determination of tizoxanide, the active metabolite of
nitazoxanide, by micellar liquid chromatography using a monolithic column. Application to
pharmacokinetic studies. Analytical Methods, 2014. 6(21): p. 8682-8689.
Matysiak-Budnik, T., F. M√©graud, and M. Heyman, In-vitro transfer of nitazoxanide across the
intestinal epithelial barrier. Journal of Pharmacy and Pharmacology, 2002. 54(10): p. 14131417.
Marcel√≠n-Jim√©nez, G., et al., Development of a method by UPLC‚ÄìMS/MS for the
quantification of tizoxanide in human plasma and its pharmacokinetic application.
Bioanalysis, 2012. 4(8): p. 909-917.
Paix√£o, P., L.F. Gouveia, and J.A.G. Morais, Prediction of drug distribution within blood.
European Journal of Pharmaceutical Sciences, 2009. 36(4‚Äì5): p. 544-554.
Prevention, C.f.D.C.a. Anthropometric Reference Data for Children and Adults: United States,
2011‚Äì2014. 2016 [cited 2019 17/10/2019]; Available from:
https://www.cdc.gov/nchs/data/series/sr_03/sr03_039.pdf.
Williams, L.R., Reference values for total blood volume and cardiac output in humans. 1994.
Bosgra, S., et al., An improved model to predict physiologically based model parameters and
their inter-individual variability from anthropometry. Crit Rev Toxicol, 2012. 42(9): p. 751767.
Yu, L.X. and G.L. Amidon, A compartmental absorption and transit model for estimating oral
drug absorption. Int J Pharm, 1999. 186(2): p. 119-125.
Peters, S., Evaluation of a Generic Physiologically Based Pharmacokinetic Model for
Lineshape Analysis. Clin Pharmacokinet 2008. 47(4): p. 261-275.

medRxiv preprint doi: https://doi.org/10.1101/2020.05.01.20087130; this version posted May 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528

42.

43.

44.

45.

46.

47.
48.

49.

50.
51.

52.

53.

54.

55.
56.

57.
58.
59.

Rodgers, T., D. Leahy, and M. Rowland, Physiologically Based Pharmacokinetic Modeling 1:
Predicting the Tissue Distribution of Moderate-to-Strong Bases. Journal of Pharmaceutical
Sciences, 2005. 94(6): p. 1259-1276.
Rodgers, T. and M. Rowland, Physiologically based pharmacokinetic modelling 2: Predicting
the tissue distribution of acids, very weak bases, neutrals and zwitterions. Journal of
Pharmaceutical Sciences, 2006. 95(6): p. 1238-1257.
Sun, D., et al., Comparison of Human Duodenum and Caco-2 Gene Expression Profiles for
12,000 Gene Sequences Tags and Correlation with Permeability of 26 Drugs. Pharmaceutical
Research, 2002. 19(10): p. 1400-1416.
Gertz, M., et al., Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A
Substrates from In Vitro Clearance and Permeability Data. Drug Metab Dispos 2010. 38(7): p.
1147-1158.
Marcellin, F., et al., Determinants of unplanned antiretroviral treatment interruptions among
people living with HIV in Yaound√©, Cameroon. Journal of Tropical Medicine and International
Health, 2008. 13(12): p. 1470-8.
Broekhuysen, J., et al., Nitazoxanide: pharmacokinetics and metabolism in man.
International Journal of Clinical Pharmacology and Therapeutics, 2000. 38(8): p. 387-394.
Belardo, G., et al., Synergistic Effect of Nitazoxanide with Neuraminidase Inhibitors against
Influenza A Viruses <em>In Vitro</em>. Antimicrobial Agents and Chemotherapy, 2015.
59(2): p. 1061-1069.
Giuseppe Belardo, S.L.F., Orlando Cenciarelli, Stefania Carta, Jean-Francois Rossignol, M.
Gabriella Santoro. Nitazoxanide, a Novel Potential Anti-Influenza Drug, Acting in Synergism
with Neuraminidase Inhibitors. in IDSA Annual Meeting. 2011. Boston, MA, USA, Available
from: https://idsa.confex.com/idsa/2011/webprogram/Paper31075.html.
Wang, M., et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel
coronavirus (2019-nCoV) in vitro. Cell Research, 2020. 30(3): p. 269-271.
Chenel, M., et al., Drug‚Äìdrug interaction predictions with PBPK models and optimal
multiresponse sampling time designs: application to midazolam and a phase I compound.
Part 1: comparison of uniresponse and multiresponse designs using PopDes. Journal of
Pharmacokinetics and Pharmacodynamics, 2008. 35(6): p. 635-659.
Nyberg, J., et al., Methods and software tools for design evaluation in population
pharmacokinetics‚Äìpharmacodynamics studies. British Journal of Clinical Pharmacology,
2015. 79(1): p. 6-17.
Stockis, A., et al., Nitazoxanide pharmacokinetics and tolerability in man during 7 days
dosing with 0.5 g and 1 g b.i.d. International Journal of Clinical Pharmacology and
Therapeutics, 2002. 40(5): p. 221-227.
Haffizulla, J., et al., Effect of nitazoxanide in adults and adolescents with acute
uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial.
The Lancet Infectious Diseases, 2014. 14(7): p. 609-618.
Tilmanis, D., et al., The susceptibility of circulating human influenza viruses to tizoxanide, the
active metabolite of nitazoxanide. Antiviral Research, 2017. 147: p. 142-148.
McCreary, E.K., J.M. Pogue, and o.b.o.t.S.o.I.D. Pharmacists, Coronavirus Disease 2019
Treatment: A Review of Early and Emerging Options. Open Forum Infectious Diseases, 2020.
7(4).
Walls, A.C., et al., Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.
Cell, 2020. 181(2): p. 281-292.e6.
Taubenberger, J.K. and D.M. Morens, The pathology of influenza virus infections. Annual
review of pathology, 2008. 3: p. 499-522.
Ranjbar, S., et al., Cytoplasmic RNA Sensor Pathways and Nitazoxanide Broadly Inhibit
Intracellular Mycobacterium tuberculosis Growth. iScience, 2019. 22: p. 299-313.

medRxiv preprint doi: https://doi.org/10.1101/2020.05.01.20087130; this version posted May 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

529

Study Highlights

530

What is the current knowledge on the topic?

531

COVID-19, an acute respiratory infection caused by SARS-CoV-2, has been declared as a pandemic by

532

the World Health Organisation. Several repurposed drugs are being evaluated but currently there are

533

no robustly validated treatment or preventative medicines or regimens. Nitazoxanide has shown in

534

vitro activity against SARS-CoV-2, influenza and several other animal and human RNA viruses.

535

What question did this study address?

536

The manuscript describes the pharmacokinetics of tizoxanide, the active metabolite of nitazoxanide

537

using a physiologically-based pharmacokinetic (PBPK) model. The validated PBPK model was used to

538

estimate the optimal doses required for SARS-CoV-2 treatment or prevention such that >90% of the

539

simulated population would have tizoxanide concentrations in the plasma and lung above the

540

reported 90% effective concentration (EC90) value of nitazoxanide for the entire dosing interval.

541

What does this study add to our knowledge?

542

There are no reported studies that identify treatment regimens of nitazoxanide for SARS-CoV-2

543

treatment or prevention. The current study provides evidence-based alternative dosing regimens of

544

nitazoxanide for SARS-CoV-2 treatment and prevention that exceeds antiviral EC90s in key tissues and

545

organs for the duration of the dosing interval.

546

How might this change clinical pharmacology or translational science?

547

Efficacy of nitazoxanide has been demonstrated for uncomplicated influenza and the presented

548

predictions may help inform nitazoxanide dose selection for COVID19 clinical trials.

549

550

Supplementary Table 1
Drug

Nitazoxanide

Average

Tizoxanide

Average
551

EC50 (¬µM)

EC50 (ng/ml)

EC90 (¬µM)

EC90 (ng/ml)

Influenza virus strain

3.2

983

26

7989

A/Puerto Rico/8/1934 (H1N1)

1.6

491

16.3

5008

A/WSN/1933 (H1N1)

3.2

983

20.8

6391

A/California/7/2009 (H1N1pdm09)

1.9

583

21.1

6483

3.2

983

26.8

8235

A/Goose/Italy/296246/2003(H1N1)

1

307

13

3994

A/Parma/06/2007(H3N2)

2.4

722

20.7

6350

(for nitazoxanide)

3.8

1000

33.9

9000

H1N1-PR8

1.9

500

22.6

6000

H1N1-WSN

1.5

400

13.5

3600

H1N1-OST-R

5.7

1500

26.4

7000

H1N1-A/GO

3.8

1000

75.4

20000

H3N2-A/FI

1.1

300

26.3

7000

H3N2-AMD-R

3.4

900

22.6

6000

FLU-B

3.0

800

31.6

8371

(for tizoxanide)

Oseltamivir-resistant

Reference

[48]

A/Parma/24/2009 (H1N1)

[49]

medRxiv preprint doi: https://doi.org/10.1101/2020.05.01.20087130; this version posted May 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

552
553

Supplementary Figure 1
A)

554
555
B)

556

medRxiv preprint doi: https://doi.org/10.1101/2020.05.01.20087130; this version posted May 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

C)

557
558
D)

559

medRxiv preprint doi: https://doi.org/10.1101/2020.05.01.20087130; this version posted May 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

E)

560
561
562

Supplementary Figure 1 Comparison of simulated and observed plasma concentration - time curve
of tizoxanide (TIZ) at fasted state. A) 500 mg, B) 1000 mg, C) 2000 mg, D) 3000 mg and E) 4000 mg

medRxiv preprint doi: https://doi.org/10.1101/2020.05.01.20087130; this version posted May 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

563

Supplementary Figure 2
A)

564
B)

565

medRxiv preprint doi: https://doi.org/10.1101/2020.05.01.20087130; this version posted May 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

C)

566
D)

567

medRxiv preprint doi: https://doi.org/10.1101/2020.05.01.20087130; this version posted May 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

E)

568
569
570
571

Supplementary Figure 2 Comparison of simulated and observed plasma concentration - time curve
of tizoxanide (TIZ) for single and multiple dosing regimen (where available) at fed state. A) 500 mg,
B) 1000 mg, C) 2000 mg, D) 3000 mg and E) 4000 mg

medRxiv preprint doi: https://doi.org/10.1101/2020.05.01.20087130; this version posted May 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

572

Supplementary Figure 3

573
574

575

576

A)

B)

medRxiv preprint doi: https://doi.org/10.1101/2020.05.01.20087130; this version posted May 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

C)

577
578

Figure 3 Predicted plasma and lung concentrations for optimal doses during fasted state at different

579

regimens reaching steady state ‚Äì A) 2900 mg BID, B) 1600 mg TID and C) 1200 mg QID. TIZ ‚Äì

580

tizoxanide, SD ‚Äì standard deviation, solid red line indicates clinical Cmax of 1 g single dose at fasted

581

state [29], solid green line represents clinical Cmax of 500 mg single dose [35] at fasted state and the

582

dotted red line represents the EC90 of nitazoxanide for SARS-CoV-2 [50].

